NEW YORK (TheStreet) -- Credit Suisse increased its price target on Celgene (CELG) to $113, increased its estimates through 2016 and set an "outperform" rating. The firm cited the company's new guidance as the reason for the move.
The stock was down 0.39% to $85.85 in pre-market trading on Friday.
Separately, TheStreet Ratings team rates CELGENE CORP as a "buy" with a ratings score of A-. TheStreet Ratings Team has this to say about their recommendation:
"We rate CELGENE CORP (CELG) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income."
You can view the full analysis from the report here: CELG Ratings ReportCELG data by YCharts